BriaCell Therapeutics (BCT) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing novel immunotherapies for cancer, particularly metastatic breast cancer.

• Lead candidate Bria-IMT™ is in a pivotal Phase 3 trial for metastatic breast cancer, with FDA Fast Track designation.

• Pipeline includes Bria-OTS™, a personalized off-the-shelf immunotherapy, and Bria-PROS+™ for prostate cancer.

• Recent clinical data show promising efficacy and safety in heavily pretreated and ADC-resistant breast cancer patients.

• Expanded access policy allows use of Bria-IMT™ for patients outside clinical trials.

Financial performance and metrics

• For the six months ended January 31, 2025: operating loss of $12.3 million; net loss of $12.2 million.

• Year ended July 31, 2024: operating loss of $33.3 million; net loss of $20.3 million.

• Cash and cash equivalents as of January 31, 2025: $5.0 million (actual), $16.2 million (as adjusted for offering).

• Share consolidation (1-for-15) effective January 24, 2025 to maintain Nasdaq listing.

Use of proceeds and capital allocation

• Estimated net proceeds of $8.84 million (up to $10.22 million with full over-allotment) from the offering.

• Proceeds intended for working capital, general corporate purposes, and advancement of business objectives.

• Management has broad discretion over use of funds; specific allocations not detailed.